NUS reported revenue, adj NI, and adj EPS of $364.2M, $17.1M, and $0.34, respectively. This compares to our estimates of $374.2M, $14.7M, and $0.30, respectively. These results were at the low end of revenue guidance and the high end of EPS guidance. Rhyz delivered $51.6M of revenue, including $47.6M from Manufacturing and $4.0M from Rhyz Other, while the Nu Skin business posted 70.5% gross margin and continued to benefit from disciplined spending as selling expense declined to 35.8% company-wide and 41.7% within the core business. Management highlighted double-digit growth in Latin America and sequential improvement across several reporting segments, noting that execution and efficiency drove EPS to the high end of the range despite a challenging macro environment. Despite a weaker than expected top line results, management remains focused on delivering on its strategic initiatives.